Address: Postbus 184
2130 AD Hoofddorp
Tel: +31 23 56 80 300
Ferring is a speciality, research-driven biopharmaceutical company that identifies, develops, manufactures and markets innovative products in the fields of urology, reproductive health, gastroenterology and endocrinology.
From its origins as a distinctly Scandinavian company, Ferring has developed into a global business with operating units in most important pharmaceutical markets around the world.
Ferring’s vision is to be the partner of choice for patients, physicians and business associates offering a leading portfolio of products and services in its key therapeutic areas, using innovative methodologies to provide tailored treatments that function on the body’s own terms.
In two rented rooms in Malmö, Sweden, Dr. Frederik Paulsen founded Nordiska Hormon Laboratoriet in 1950, which in 1954 changed its name to Ferring. He named the company after the strong, closely knit community of people originating from the island Föhr who called themselves Feringers, and spoke Fering.
World leader in peptide hormones, Ferring became a pioneer in developing and selling pharmaceutical products based upon natural, pituitary-produced peptide hormones. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and correct abnormalities, thus playing an invaluable role in the treatment of life-threatening conditions.
Five decades later, Dr. Paulsen’s predictions have proved remarkably accurate. Today, peptides from Ferring are widely used in Ferring’s treatments. The development of the product MINIRIN (desmopressin), used to treat nocturnal enuresis, or bedwetting, formed the basis of Ferring’s international expansion and boosted revenues from the late 1980s on.
Gynaecology (Fertility and obstetrics), urology, gastroenterology, Child endocrinology and Child hematology.
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in…
Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective…
In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager Managed Equipment Services (MES) Europe, and Dick Blesing (DB),…
DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to help overcome them. The Vice President and Commercial Director discuss how the services of…
Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses…
After having successfully acquired its first dialysis center in the Netherlands, Fresenius Medical Care, the market leader for kidney failure products and services, is looking to develop more partnerships with…
Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens,…
Kees Smaling, Managing Director of Siemens Healthcare, which recently completed its first Dutch (and European) hospital financing, explains the strategic thinking that sustains Siemens’ shift to become a more comprehensive…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
See our Cookie Privacy Policy Here
